Taro Pharmaceutical Industries Ltd. (TARO)
Jun 24, 2024 - TAR was delisted (reason: acquired by Sun Pharma)
42.97
0.00 (0.00%)
Inactive · Last trade price
on Jun 21, 2024
TARO Revenue
In the fiscal year ending March 31, 2024, Taro Pharmaceutical Industries had annual revenue of $629.18M with 9.81% growth. Taro Pharmaceutical Industries had revenue of $164.94M in the quarter ending March 31, 2024, with 12.52% growth.
Revenue (ttm)
$629.18M
Revenue Growth
+9.81%
P/S Ratio
2.57
Revenue / Employee
$404,879
Employees
1,554
Market Cap
1.62B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 629.18M | 56.23M | 9.81% |
Mar 31, 2023 | 572.95M | 11.61M | 2.07% |
Mar 31, 2022 | 561.35M | 12.38M | 2.25% |
Mar 31, 2021 | 548.97M | -95.80M | -14.86% |
Mar 31, 2020 | 644.77M | -25.12M | -3.75% |
Mar 31, 2019 | 669.89M | 7.98M | 1.21% |
Mar 31, 2018 | 661.91M | -217.47M | -24.73% |
Mar 31, 2017 | 879.39M | -71.36M | -7.51% |
Mar 31, 2016 | 950.75M | 87.81M | 10.18% |
Mar 31, 2015 | 862.94M | 103.66M | 13.65% |
Mar 31, 2014 | 759.29M | 88.33M | 13.16% |
Mar 31, 2013 | 670.95M | 127.87M | 23.55% |
Mar 31, 2012 | 543.08M | 37.41M | 7.40% |
Dec 31, 2011 | 505.67M | 113.13M | 28.82% |
Dec 31, 2010 | 392.54M | 36.60M | 10.28% |
Dec 31, 2009 | 355.94M | 26.90M | 8.18% |
Dec 31, 2008 | 329.04M | 9.48M | 2.97% |
Dec 31, 2007 | 319.55M | 67.29M | 26.67% |
Dec 31, 2006 | 252.27M | -36.35M | -12.60% |
Dec 31, 2005 | 288.62M | 17.64M | 6.51% |
Dec 31, 2004 | 270.99M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionTARO News
- 2 months ago - Investors Are Invited By The Schall Law Firm To Join A Securities Fraud Case Against Taro Pharmaceutical Industries Ltd. - Accesswire
- 2 months ago - Taro Pharmaceutical Industries Ltd Is Being Sued For Securities Law Violations And The Schall Law Firm Urges Shareholder Participation - Accesswire
- 5 months ago - Sun Pharma Completes Taro Merger - PRNewsWire
- 6 months ago - Taro Shareholders Approve Merger with Sun Pharma - PRNewsWire
- 6 months ago - Taro Provides Results for Year Ended March 31, 2024 - Business Wire
- 6 months ago - Taro to Release Full Year Results on May 20, 2024 - Business Wire
- 7 months ago - Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote “FOR” Taro Sun Pharma Merger - Business Wire
- 7 months ago - TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro Pharmaceutical Industries Ltd. - TARO - Business Wire